Lambert-Eaton myasthenic syndrome – a misdiagnosed condition
Закрыть
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
794 17
Ultima descărcare din IBN:
2023-02-07 12:31
Căutarea după subiecte
similare conform CZU
616.831.8-009.17 (2)
Инфекционные заболевания. Инфекционные лихорадки (972)
SM ISO690:2012
FALA, Paula, COJOCARU, Ina, CHETRARI, Larisa, GAVRILIUC, Pavel, SANGHELI, Marina, LISNIC, Vitalie. Lambert-Eaton myasthenic syndrome – a misdiagnosed condition. In: Moldovan Medical Journal, 2019, nr. 1(62), pp. 46-49. ISSN 2537-6373. DOI: https://doi.org/10.5281/zenodo.2590020
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Moldovan Medical Journal
Numărul 1(62) / 2019 / ISSN 2537-6373 /ISSNe 2537-6381

Lambert-Eaton myasthenic syndrome – a misdiagnosed condition

DOI:https://doi.org/10.5281/zenodo.2590020
CZU: 616.831.8-009.17

Pag. 46-49

Fala Paula12, Cojocaru Ina2, Chetrari Larisa2, Gavriliuc Pavel21, Sangheli Marina12, Lisnic Vitalie21
 
1 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
2 Diomid Gherman Institute of Neurology and Neurosurgery
 
 
Disponibil în IBN: 13 aprilie 2019


Rezumat

Background: Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction. Clinical features include proximal muscle weakness, markedly in the lower limbs, reduced deep tendon reflexes that can increase after exercise, and autonomic disturbances. The clinical picture as well as knowledge of the laboratory test that accompany LEMS will permit early recognition of the disease, that is crucial because it is often associated with malignancy, especially small cell lung cancer (SCLC). In this article we present a patient with proximal muscle weakness and typical changes on repetitive nerve stimulation, as well as a short literature review on the topic. Conclusions: The diagnosis of LEMS is usually made on clinical grounds. The diagnosis is confirmed by electrophysiological testing, main features including decrement response on slow repetitive nerves stimulation (3Hz), and an increment of more than 100% in CMAP amplitude after brief exercise, or high frequency repetitive stimulation (30-50 Hz). Immunological panel assay with positive P/Q-type VGCC antibody is strongly suggestive of LEMS. While symptomatic treatment with 3,4 – diaminopyridine is available, one of the main priorities is evaluation for underlying malignancies in these patients, the most common being SCLC. Evaluation of patients with LEMS and no known cancer should start with CT of the chest, abdomen and pelvis. Brain imaging is recommended if focal neurological signs are present. If the initial evaluation of the patient is negative, repeated screening for malignancy after 6 months and up to two years is recommended.

Cuvinte-cheie
Lambert-Eaton myasthenic syndrome, cancer, weakness, increment.